Piper Sandler lowered the firm’s Carvykti revenue forecast to $290M from $335M in Q4 and to $1.63B from $1.75B in 2025 as Legend Biotech (LEGN) and Johnson & Johnson (JNJ) work to build supply. Carvykti “remains the Gold Standard with demand far outpacing supply,” the analyst tells investors in a research note. The firm says Legend and J&J are working to increase supply to 10,000 autologous doses by the end of 2025. Piper reiterates an Overweight rating on Legend Biotech with a $78 price target.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LEGN:
- Legend Biotech Announces Employee Transition Agreement
- Legend Biotech management to meet with Piper Sandler
- Arcellx price target raised to $114 from $106 at UBS
- Legend Biotech’s CARVYKTI® Boosts Myeloma Treatment Success
- Legend Biotech’s Phase 3 study of CARVYKTI shows ‘improved disease negativity’
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
